Joseph Bryan, MD
Retina Specialist · Phoenix, AZNPI 1881686558
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (56.9%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 94.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $51,537 and has fallen 99.0% since, to $529 in 2025.
Across 95 payments — averaging $925.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$83K
- Alimera Sciences, Inc.$2K
- Bausch & Lomb Americas Inc.$665
- Genentech USA, Inc.$570
- Regeneron Healthcare Solutions, Inc.$552
- AbbVie$439
- plus $1K from 14 others
Across 3 payments — averaging $36,908 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$111K
What the payments were for
- Food & beverage$5,4876%
- Gifts$190%
- Ownership interest$32,38337%
- Other$50,00057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 9 | $82,825 |
| Alimera Sciences, Inc. | 6 | $1,560 |
| Bausch & Lomb Americas Inc. | 11 | $665 |
| Genentech USA, Inc. | 17 | $570 |
| Regeneron Healthcare Solutions, Inc. | 17 | $552 |
| AbbVie(2 entities) | 12 | $439 |
| Dutch Ophthalmic, USA | 2 | $302 |
| Novartis | 3 | $142 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $137 |
| ANI Pharmaceuticals, Inc. | 2 | $132 |
| Alcon | 1 | $113 |
| Eyepoint US, Inc. | 1 | $109 |
| Astellas Pharma US Inc | 3 | $89 |
| Mallinckrodt Enterprises LLC | 2 | $55 |
| Coherus Oncology, Inc. | 2 | $48 |
| Genentech, Inc. | 1 | $47 |
| Regeneron | 1 | $47 |
| Harrow Eye, LLC | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$1,560
- YUTIQ$1,013
- STELLARIS$500
- EVA Ophthalmic Surgical System$302
- VABYSMO$154
- STELLARIS PC$121
- PanOptix$113
- Humira$112
- EYLEA$100
How this compares
$87,890 in reported general payments places this provider in the 75th percentile of 30 retina specialist providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 209 | $10,062 |
| ProlensaBromfenac Sodium | 24 | $9,467 |
| Loteprednol Etabonate | 31 | $6,060 |
| Brimonidine Tartrate | 70 | $4,190 |
| Difluprednate | 34 | $2,860 |
| Ketorolac Tromethamine | 114 | $2,462 |
| Ofloxacin | 102 | $1,042 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 56 | $992 |
| Dorzolamide Hcl | 19 | $626 |
| Timolol Maleate | 60 | $555 |
| MoxifloxacinMoxifloxacin Hcl | 18 | $436 |
| Latanoprost | 37 | $426 |
| ErythromycinErythromycin Base | 14 | $156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $137 | $15,52655 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 30 retina specialist providers in Arizona.
Other retina specialist in Phoenix
- Jordan GraffPhoenix$483K
- Rahul ReddyPhoenix$333K
- Henry KwongPhoenix$147K
- Benjamin BakallPhoenix$137K
- Jaime GaitanPhoenix$114K
- Stephen de SouzaPhoenix$95K
- Alan GordonPhoenix$86K
- Suhail AlamPhoenix$24K
- Rima PatelPhoenix$19K
- Matthew WelchPhoenix$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.